BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27806318)

  • 21. Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast.
    Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Oncol Rep; 2016 Mar; 35(3):1511-8. PubMed ID: 26676988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
    Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
    Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibroepithelial lesions; The WHO spectrum.
    Krings G; Bean GR; Chen YY
    Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Periductal Stromal Tumor of the Breast with a
    Anderson B; Marotti JD; Lefferts JA; Muller KE
    Int J Surg Pathol; 2023 Dec; 31(8):1626-1631. PubMed ID: 36823780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteosarcoma mimic in the breast: A recurrent malignant phyllodes tumour harbouring MED12 and hTERT mutations.
    Tokoyoda M; Adachi S; Ishida Y; Yamazaki K
    Cytopathology; 2018 Aug; 29(4):383-385. PubMed ID: 29633481
    [No Abstract]   [Full Text] [Related]  

  • 26. Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
    Ng CCY; Md Nasir ND; Loke BN; Tay TKY; Thike AA; Rajasegaran V; Liu W; Lee JY; Guan P; Lim AH; Chang KTE; Gudi MA; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Yip GWC; Bay BH; Tan P; Teh BT; Tan PH
    Mod Pathol; 2021 Jul; 34(7):1320-1332. PubMed ID: 33727697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women.
    Darooei M; Khan F; Rehan M; Zubeda S; Jeyashanker E; Annapurna S; Shah A; Maddali S; Hasan Q
    J Cell Biochem; 2019 Jan; 120(1):182-191. PubMed ID: 30230586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.
    Lim WK; Ong CK; Tan J; Thike AA; Ng CC; Rajasegaran V; Myint SS; Nagarajan S; Nasir ND; McPherson JR; Cutcutache I; Poore G; Tay ST; Ooi WS; Tan VK; Hartman M; Ong KW; Tan BK; Rozen SG; Tan PH; Tan P; Teh BT
    Nat Genet; 2014 Aug; 46(8):877-80. PubMed ID: 25038752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
    Otsuji K; Sasaki T; Tanabe M; Seto Y
    Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Chang HY; Koh VCY; Md Nasir ND; Ng CCY; Guan P; Thike AA; Teh BT; Tan PH
    J Clin Pathol; 2020 Jan; 73(1):51-56. PubMed ID: 31662438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study.
    Tan BY; Md Nasir ND; Chang HY; Ng CCY; Guan P; Nagarajan S; Rajasegaran V; Lee JY; Lim JQ; Thike AA; Teh BT; Tan PH
    Mod Pathol; 2020 Sep; 33(9):1732-1745. PubMed ID: 32322022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions.
    Sim Y; Ng GXP; Ng CCY; Rajasegaran V; Wong SF; Liu W; Guan P; Nagarajan S; Ng WY; Thike AA; Lim JCT; Nasir NDBM; Tan VKM; Madhukumar P; Yong WS; Wong CY; Tan BKT; Ong KW; Teh BT; Tan PH
    BMC Med Genomics; 2019 Oct; 12(1):142. PubMed ID: 31647027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are both distinct epithelial and stromal cells molecular analysis from phyllodes tumors versus fibroadenoma components affected in breast fibroepithelial progression?
    Waitzberg ÂFL; Ferreira ENE; Pinilla M; Pineda P; Malinverni ACM; Soares FA; Carraro DM
    Acta Cir Bras; 2023; 38():e386823. PubMed ID: 38055384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor.
    Piscuoglio S; Geyer FC; Burke KA; Murray MP; Ng CK; Mota A; Marchio C; Berman SH; Norton L; Brogi E; Weigelt B; Reis-Filho JS
    NPJ Breast Cancer; 2016; 2():16035. PubMed ID: 28721388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast.
    Geyer FC; Burke KA; Piscuoglio S; Ng CKY; Papanastasiou AD; Marchiò C; Selenica P; Edelweiss M; Murray MP; Brogi E; Soslow RA; Rubin BP; Norton L; Reis-Filho JS; Weigelt B
    Mol Oncol; 2017 Aug; 11(8):913-926. PubMed ID: 28267263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
    Gatalica Z; Vranic S; Ghazalpour A; Xiu J; Ocal IT; McGill J; Bender RP; Discianno E; Schlum A; Sanati S; Palazzo J; Reddy S; Pockaj B
    Oncotarget; 2016 Jan; 7(2):1707-16. PubMed ID: 26625196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study.
    Lv S; Niu Y; Wei L; Liu Q; Wang X; Chen Y
    Breast Cancer Res Treat; 2008 Dec; 112(3):411-8. PubMed ID: 18189161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
    Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
    Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast.
    Takizawa K; Yamamoto H; Taguchi K; Ohno S; Tokunaga E; Yamashita N; Kubo M; Nakamura M; Oda Y
    Hum Pathol; 2016 Sep; 55():30-8. PubMed ID: 27137988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mRNA expression profiling of phyllodes tumours of the breast: identification of genes important in the development of borderline and malignant phyllodes tumours.
    Jones AM; Mitter R; Poulsom R; Gillett C; Hanby AM; Tomlinson IP; Sawyer EJ;
    J Pathol; 2008 Dec; 216(4):408-17. PubMed ID: 18937276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.